Product image of Ostenil 70 (Alendronate Sodium Monohydrate) supplied by GNH India

Ostenil 70

Active Ingredient:
Alendronate Sodium Monohydrate
Origin:
EU

Ostenil 70 (Alendronate Sodium Monohydrate)

Alendronate sodium monohydrate, the active ingredient in Ostenil 70, is a bisphosphonate presented as a tablet for oral use. It treats osteoporosis and other bone‑loss conditions in post‑menopausal women and men at risk of fracture. GNH India supplies Ostenil 70 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Ostenil 70 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva Pharmaceuticals Polska Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ostenil 70 is a bisphosphonate that acts on bone metabolism to improve skeletal strength.

  • Osteoporosis: reduces the risk of vertebral and hip fractures in post‑menopausal women and men.
  • Paget’s disease of bone: normalises abnormal bone turnover and alleviates bone pain.
  • Secondary osteoporosis: helps maintain bone density in patients receiving long‑term glucocorticoid therapy.

How It Works

  • Alendronate sodium monohydrate binds with high affinity to hydroxy‑apatite crystals at sites of active bone remodeling. When osteoclasts resorb bone containing the drug, it is internalised and inhibits farnesyl pyrophosphate synthase within the mevalonate pathway, leading to loss of osteoclast function and apoptosis, thereby reducing bone resorption.

Side Effects

Adverse reactions to alendronate are reported across a spectrum of frequency.

Common Side Effects

  • Upper gastrointestinal irritation: dyspepsia, heartburn or abdominal discomfort.
  • Musculoskeletal pain: transient bone, joint or muscle aches.
  • Nausea or vomiting.
  • Constipation or diarrhoea.
  • Headache.
  • Skin rash.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw (ONJ): exposed necrotic bone in the maxillofacial region.
  • Atypical femoral fracture: low‑energy fracture of the subtrochanteric or diaphyseal femur.
  • Severe esophagitis or oesophageal ulceration.
  • Acute phase reaction: fever, myalgia and flu‑like symptoms.
  • Hypocalcaemia: low serum calcium levels, especially in patients with vitamin D deficiency.
  • Severe allergic reaction: anaphylaxis or angioedema.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient history and baseline labs.

  • Renal function: assess creatinine clearance; avoid in severe renal impairment.
  • Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk.
  • Gastro‑intestinal disorders: avoid in patients with active oesophageal disease.
  • Concomitant medications: review for drugs that may irritate the oesophagus or affect absorption.
  • Pregnancy and lactation: contraindicated; advise effective contraception.
  • Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Alendronate may interact with several medicines that influence absorption or bone metabolism.

Major Interactions (Avoid)

  • Calcium‑containing antacids or supplements: taken within 30 min of alendronate reduces its absorption.
  • Proton pump inhibitors (e.g., omeprazole): may diminish bioavailability when used chronically.
  • Intravenous bisphosphonates: concurrent use increases risk of ONJ and atypical fractures.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal irritation.
  • Corticosteroids: additive risk of bone loss and gastrointestinal side effects.
  • Loop diuretics: can exacerbate hypocalcaemia if calcium intake is insufficient.

Frequently Asked Questions

Ostenil 70 contains alendronate sodium monohydrate, a bisphosphonate indicated for the treatment and prevention of osteoporosis, for management of Paget’s disease of bone, and for secondary osteoporosis associated with long‑term glucocorticoid therapy.

Alendronate binds to hydroxy‑apatite at active bone‑remodeling sites. When osteoclasts ingest the drug, it blocks farnesyl pyrophosphate synthase in the mevalonate pathway, impairing osteoclast function and inducing apoptosis, which reduces bone resorption and improves bone density.

The prescribed dose of alendronate is determined by the treating clinician based on the patient’s condition, renal function and risk profile. Dosage regimens are individualized and should follow the prescriber’s instructions.

Alendronate is classified as contraindicated in pregnancy and lactation because it may affect fetal bone development. Women of child‑bearing potential should use effective contraception while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ostenil 70 (alendronate) is an oral bisphosphonate with a well‑established efficacy profile for osteoporosis and Paget’s disease. Compared with weekly or monthly formulations of risedronate or ibandronate, alendronate is typically taken daily or weekly, offering flexibility but requiring strict administration rules to minimise gastrointestinal irritation.

Store tablets at ambient temperature, below 25 °C, in the original blister pack. Protect from moisture and direct sunlight. Do not refrigerate or freeze the product.

Ostenil 70 tablets are taken orally with a full glass of plain water, first thing in the morning, at least 30 minutes before any food, drink or other medication. Patients should remain upright for at least 30 minutes after ingestion to reduce oesophageal irritation.

Serious adverse events include osteonecrosis of the jaw, atypical femoral fractures, severe oesophagitis or ulceration, and acute hypocalcaemia. Patients should be monitored for persistent jaw pain, unexplained thigh or groin pain, and signs of gastrointestinal bleeding.

Contraindications include patients with severe renal impairment (creatinine clearance <30 mL/min), active oesophageal disorders, inability to sit or stand upright for 30 minutes, known hypersensitivity to alendronate, and pregnant or breastfeeding women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Alendronate Sodium Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT